β-干扰素1b用于治疗多发性硬化症。
Interferon-beta1b for the treatment of multiple sclerosis.
作者信息
Lam Sum, Wang Shan, Gottesman Malcolm
机构信息
St. John's University, College of Pharmacy and Allied Health Professions, Department of Clinical Pharmacy Practice, St. Albert's Hall Room 114, 8000 Utopia Parkway, Queens, New York, NY 11439, USA.
出版信息
Expert Opin Drug Metab Toxicol. 2008 Aug;4(8):1111-7. doi: 10.1517/17425255.4.8.1111.
BACKGROUND
Multiple sclerosis is a debilitating autoimmune disorder that causes disability in young adults.
OBJECTIVE
To review the efficacy and safety of IFN-beta1b in the management of relapsing-remitting and secondary progressive multiple scleroses and clinical isolated syndrome.
METHODS
A MEDLINE (1966-May 2007) search of clinical trials using the terms 'multiple sclerosis' and 'interferon' was performed. Manual bibliographic search was conducted. English-language articles were evaluated.
RESULTS
IFN-beta1b is more efficacious than placebo and at least as efficacious as IFN-beta1a or glatiramer for the management of relapsing-remitting multiple sclerosis. IFN-beta1b also delayed the time to diagnosis of definite multiple sclerosis and reduced brain lesion burden in patients with clinical isolated syndrome. More long-term, large scale clinical data are warranted to ascertain its relative efficacy compared to other treatments.
CONCLUSION
IFN-beta1b is an effective treatment for multiple sclerosis. Common side effects are lymphopenia, injection site reactions, asthenia, flu-like symptoms and headache.
背景
多发性硬化症是一种使人衰弱的自身免疫性疾病，会导致年轻人残疾。
目的
综述β-1b干扰素在复发缓解型和继发进展型多发性硬化症以及临床孤立综合征治疗中的疗效和安全性。
方法
利用“多发性硬化症”和“干扰素”等检索词对MEDLINE（1966年至2007年5月）中的临床试验进行检索。进行了手工文献检索。对英文文章进行评估。
结果
在复发缓解型多发性硬化症的治疗中，β-1b干扰素比安慰剂更有效，且至少与β-1a干扰素或醋酸格拉替雷一样有效。β-1b干扰素还延迟了确诊多发性硬化症的时间，并减轻了临床孤立综合征患者的脑损伤负担。需要更多长期、大规模的临床数据来确定其与其他治疗方法相比的相对疗效。
结论
β-1b干扰素是治疗多发性硬化症的有效药物。常见副作用有淋巴细胞减少、注射部位反应、乏力、流感样症状和头痛。
Zotero 插件